Antibe Therapeutics Inc. ATBPF
0.22 +0.22
Day range unavailable
52-week range unavailable
- Market cap
- 11.43M
- Earnings date
- Jul 4, 2024
No chart data for this range yet.
Next earnings
Jul 4, 2024
Expected Jul 4, 2024. Consensus EPS estimate -0.10.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 4, 2024 | Mar 1, 2024 | -0.10 | — | — | — |
| Feb 14, 2024 | Dec 1, 2023 | -0.09 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -0.09 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -0.08 | — | — | — |
| Jun 29, 2023 | Mar 1, 2023 | -0.07 | — | — | — |
| Feb 14, 2023 | Dec 1, 2022 | -0.09 | — | — | — |
News
Analyzing Evelo Biosciences (NASDAQ:EVLO) & Antibe Therapeutics (OTCMKTS:ATBPD) 
Antibe Announces Appointment of Receiver 
Antibe Provides Update on CCAA Proceedings 
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act 
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act 
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting 
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma 
Antibe Reports Q3 2024 Interim Financial and Operating Results 
Antibe Extends Early Warrant Exercise Incentive Program 
Antibe Announces Early Warrant Exercise Incentive Program
Your note
Sign in to keep a note on ATBPF — it syncs with the Stock Master app.